Fifth Third Bancorp
EGRX

Fifth Third Bancorp’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Fifth Third Bancorp’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-43
Closed -$836 – 2711
2023
Q2 		$836 Buy
+43
New +$1.02K ﹤0.01% 2526
2023
Q1 		– Sell
-25
Closed -$731 – 2845
2022
Q4 		$731 Hold
25
– – ﹤0.01% 2571
2022
Q3 		$1K Buy
+25
New +$917 ﹤0.01% 2616

Other funds holding EGRX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Fifth Third Bancorp's EGRX Position: Q3 2023 in Review

Fifth Third Bancorp sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q3 2023, closing a stake of 43 shares — an estimated $836 sold.

Fifth Third Bancorp first reported a position in EGRX in Q3 2022 and held it in 3 quarters. The position peaked at $1K in Q3 2022. 107 funds tracked by Wall St. Rank hold EGRX as of Q3 2023.

  • Fifth Third Bancorp reported no remaining Eagle Pharmaceuticals, Inc. position as of Q3 2023 after selling out during the quarter.
  • Fifth Third Bancorp sold 43 Eagle Pharmaceuticals, Inc. shares in Q3 2023, an estimated $836.
  • Fifth Third Bancorp first reported a position in Eagle Pharmaceuticals, Inc. in Q3 2022 and held it in 3 quarters.
  • Fifth Third Bancorp's Eagle Pharmaceuticals, Inc. position peaked at $1K in Q3 2022.
  • 107 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q3 2023.

Based on Fifth Third Bancorp's 13F filing for Q3 2023, filed 31 Oct 2023.